A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.

Key facts

Study ID

NCT07428525

Run by

Amgen

People needed

36

Starts

2025-03-14

Expected to finish

2026-02-26

Last updated by the study team

2026-03-11

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults 18 to 75 years of age, male or female.
• Body mass index ≥ 22 kg/m\^2 at screening.
• For participants with normal hepatic function:
• In good health with no clinically significant findings from medical history, physical exam, electrocardiogram (ECG), vital signs, or laboratory tests.
• Systolic blood pressure (BP) 90-150 mmHg and diastolic BP 50-100 mmHg; pulse 40-110 bpm.
• Stable body weight (< 5 kg change) and no recent dietary modifications within 3 months.
• For participants with hepatic impairment:
• Documented Child-Pugh Class A (mild), B (moderate), or C (severe) hepatic impairment.
• Clinically stable chronic liver disease (e.g., cirrhosis, hepatitis B, alcoholic liver disease, or stable hepatitis C).
• Systolic BP ≤ 170 mmHg and diastolic BP ≤ 100 mmHg.
• Willing to use reliable contraception (if of childbearing potential) or practice abstinence through 16 weeks after dosing.

You may not qualify if…

• Any unstable medical condition (e.g., recent hospitalization or major surgery).
• History of acute or chronic pancreatitis within 1 year or lipase/amylase > 2× ULN at screening.
• Endocrine disorder that can cause obesity (e.g., Cushing's syndrome).
• Significant cardiac conditions (e.g., clinically meaningful arrhythmias, 2nd/3rd-degree AV block, QT Interval Corrected Using Fridericia's Formula (QTcF) >450 msec men / >470 msec women for normal hepatic group; > 490 msec men / > 500 msec women for hepatic impairment).
• Estimated glomerular filtration rate < 60 mL/min/1.73 m\^2 (normal/mild) or < 50 mL/min/1.73 m\^2 (moderate/severe impairment).
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
• Uncontrolled thyroid disease or clinically significant gastroparesis.
• Prior bariatric surgery within 6 months.
• Poor venous access.
• Positive Human Immunodeficiency Virus (HIV) test.
• Hypersensitivity to AMG 133 or its components.
• Current use of GLP-1 or GIP receptor agents within 3 months.
• Pregnancy or lactation, or unwillingness to follow contraception requirements.
• History of substance or alcohol abuse within 1 year or current alcohol intake > 21 units/week (men) or > 14 units/week (women).
• Positive test for hepatitis B surface antigen or active hepatitis C (with unstable disease).
• Diabetes mellitus not meeting glycemic cutoffs (hemoglobin A1C ≥ 6.5 % for normal hepatic group or > 11 % for hepatic impairment group).
• Active malignancy (within 18 months for hepatic impairment group; within 5 years for normal hepatic group).
• Hepatic encephalopathy Grade ≥ 3 (uncontrolled) or severe uncontrolled ascites.
• Organ transplant recipients or those on immunosuppressants.
• Participation in another clinical trial within 30 days or 5 drug half-lives (whichever is longer).

Where it is running

• Clinical Pharmacology Of Miami, LLC — Miami, Florida, United States
• Panax Clinical Research — Miami Lakes, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States
• The Texas Liver Institute, Inc. — San Antonio, Texas, United States
• Pinnacle Clinical Research San Antonio — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.